| Title |
Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men
|
|---|---|
| Published in |
Psychopharmacology, November 1995
|
| DOI | 10.1007/bf02246085 |
| Pubmed ID | |
| Authors |
J. Guldner, L. Trachsel, C. Kratschmayr, B. Rothe, F. Holsboer, A. Steiger |
| Abstract |
Preclinical data suggest that the imidazodiazepinone derivative bretazenil (Ro 16-6028) has anxiolytic and anticonvulsant properties with only weak sedative effects. We examined the influence of oral administration of 1 mg bretazenil on the sleep EEG and the concomitant nocturnal secretion of cortisol, growth hormone and prolactin in ten healthy young men. After bretazenil we found a significant increase in stage 2 sleep and a significant reduction in stage 3 sleep. REM latency was prolonged. Spectral analysis of sleep-EEG power revealed a decrease in delta and in theta power and an increase in sigma power. We found no significant influence on sleep onset latency or on intermittent wakefulness. Bretazenil prompted a significant decrease in cortisol secretion and a significant increase in prolactin release. It had no major influence on growth hormone secretion. |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 10% |
| Canada | 1 | 5% |
| Unknown | 17 | 85% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 4 | 20% |
| Researcher | 4 | 20% |
| Student > Ph. D. Student | 3 | 15% |
| Student > Bachelor | 2 | 10% |
| Professor > Associate Professor | 2 | 10% |
| Other | 2 | 10% |
| Unknown | 3 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 25% |
| Agricultural and Biological Sciences | 3 | 15% |
| Neuroscience | 3 | 15% |
| Psychology | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 5 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2020.
All research outputs
#7,453,479
of 22,786,691 outputs
Outputs from Psychopharmacology
#2,099
of 5,345 outputs
Outputs of similar age
#7,339
of 25,340 outputs
Outputs of similar age from Psychopharmacology
#14
of 38 outputs
Altmetric has tracked 22,786,691 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,345 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 25,340 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.